Document is current
Any future updates will be listed below
-
Authors
Gouda, Alaa Refaat https://orcid.org/0009-0009-7331-4848
El-Bassiouny, Noha A https://orcid.org/0000-0001-9277-2910
Salahuddin, Ahmad https://orcid.org/0000-0002-7382-4284
Hamouda, Emad Hamdy https://orcid.org/0009-0009-9864-9230
Kassem, Amira B. https://orcid.org/0000-0003-4195-6036
-
Clinical Trials BETA
Clinical trials referenced in this document:
pactr202209548995270 at Pan African Clinical Trial RegistryDocuments that mention this clinical trial
Repurposing of high-dose N-acetylcysteine as anti-inflammatory, antioxidant and neuroprotective agent in moderate to severe traumatic brain injury patients: a randomized controlled trial
https://doi.org/10.1007/s10787-025-01706-0
-
Funding
Funding for this research was provided by:
Damanhour University
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 15 February 2025
First Online: 10 April 2025
Declarations
:
: No conflicts of interest were declared by the authors.
: An open-label single-centered randomized controlled trial in patients with moderate to severe TBI was conducted from September 2022 to January 2024 at Alexandria Main University Hospital, Alexandria University, Alexandria, Egypt. The study was conducted in accordance with the ethical standards laid down in the 1964 Declarations of Helsinki and its later amendments. The study protocol was approved by the Research Ethics Committee of the Faculty of Pharmacy, Damanhour University (Reference no: 1121PP46) and by the Ethics Committee on Human Research of the Faculty of Medicine, Alexandria University (Reference no: 0106942). The study protocol was registered before patient enrollment at pactr.org (PACTR202209548995270).
: Informed consent was obtained from all patients’ legally authorized representatives included in the study.
: Not applicable.
